RedCarpetLife
Billionaires
Business
Luxury Lifestyle
Lists
World Leaders
Fashion & Style
Tools
Featured Articles
Learn Finance with Arthalogy
Advertise with RedCarpetLife
Contact Us
Careers at RedCarpetLife
Meet Our Authors
About Us
Correction or Feedback
Terms of Use
Privacy Policy
238
In the world today
Zhu Yi

Zhu Yi

Z. Yi
-0.14% | - $-17.13M
$12.44 B ₹ 1.13 Lk Cr
Real Time Net Worth #238 Ranking as of 21 Feb 2026 By Forbes
Check Your Ranking

More on Zhu Yi

Gender

Male

Age

63Y

Country

China

Born On

January, 1963

Deceased

No

Relationship Status

Unknown

Children

Unknown

Education

Sichuan University - Bachelor'S & PhD

Designation Info :

Self-Made

Yes

Entrepreneur Type

Self-Made (Pharmaceuticals)

Primary Organization

Biokin Pharmaceutical

Titles

Chairman

Sources of Wealth

Pharmaceuticals

Industry

Healthcare, Pharmaceuticals

About Zhu Yi

Z hu Yi is the founder and chairman of Biokin Pharmaceutical, a Chinese biopharmaceutical company specializing in innovative drugs for cancer and autoimmune diseases. He holds a master's degree in biophysics from Fudan University and a PhD in enterprise management from Sichuan University. Before becoming an entrepreneur, he was a professor of immunology and microbiology at West China University of Medical Sciences.

Zhu founded Biokin in 1996 and has led its growth into a major player in the Chinese pharma sector. The company made headlines with a massive $8.4 billion deal with Bristol Myers Squibb for a cancer drug developed by its US subsidiary, SystImmune. Biokin listed on the Shanghai Stock Exchange in 2023. Zhu's background bridges academic science and commercial drug development.

Advertisement

Quick Reads

Early Life and Background

Zhu Yi is a Chinese businessman, the Chairman of Biokin Pharmaceutical, a developer of drugs including anesthesia injections, cancer drugs as well as traditional Chinese medicine treatments.

Prior to becoming an entrepreneur, Zhu taught immunology and microbiology at West China University of Medical Sciences. The company went public in Shanghai in 2023, raising $136 million, and has been seeking a Hong Kong IPO since 2024.

  • Core Company: Biokin Pharmaceutical (Drug developer).
  • Key Deal: U.S. subsidiary SystImmune signed an $8.4 billion deal with Bristol Myers Squibb in 2023.
  • Prior Career: Taught immunology and microbiology at a medical university.

Career Journey of Zhu Yi

Zhu Yi leveraged his academic expertise in immunology and microbiology to found Biokin Pharmaceutical. His structural achievement lies in developing a drug pipeline so promising that its U.S. subsidiary, SystImmune, secured an $8.4 billion deal with Bristol Myers Squibb in 2023 to jointly develop a potential cancer treatment worldwide.

The company's recent 2023 Shanghai IPO and its plan for a subsequent Hong Kong listing highlight its successful scaling in the highly valued biotech sector.

Advertisement

Zhu Yi's Timeline

Pre-2023:

Taught immunology and microbiology at West China University of Medical Sciences.

2023:

Biokin executes its IPO in Shanghai; U.S. subsidiary SystImmune signs $8.4 billion deal with Bristol Myers Squibb.

Ongoing:

Continues as Chairman.

Major Business Ventures and Investments

Zhu Yi's wealth is concentrated in his founding equity and continued leadership of the publicly traded pharmaceutical developer, Biokin Pharmaceutical.

  • Biokin Pharmaceutical (Chairman): Developer of drugs for anesthesia, cancer, and traditional Chinese medicine.
  • SystImmune (Subsidiary): Partnered with Bristol Myers Squibb on an $8.4 billion cancer treatment deal.
  • IPO: Listed in Shanghai in 2023, raising $136 million.

Advertisement

Philanthropy and Social Impact

Fashion, Style, and Lifestyle

Advertisement

Quotes and Philosophy

No publicly available quotes.

Fun Facts & Trivia

  • He is the Chairman of Biokin Pharmaceutical, a developer of cancer drugs.
  • Biokin's U.S. subsidiary signed an $8.4 billion deal with Bristol Myers Squibb in 2023.
  • He previously taught immunology and microbiology at West China University of Medical Sciences.
  • The company went public in Shanghai in 2023, raising $136 million.

Advertisement

More Profiles

Rufino Vigil Gonzalez

Rufino Vigil Gonzalez

#1326

+0.56% | +$17.43M

Maren Otto

Maren Otto

#1512

+0.91% | +$24.70M

You May Like

Sources & References

This profile is compiled from verified biographical and financial records:

  • Wealth Data: Real-time tracking and historical data from Forbes Billionaires and the Bloomberg Billionaires Index.
  • Biographical Records: Educational and career history sourced from Reuters, The Wall Street Journal, and official university alumni directories.
  • Regulatory Filings: Shareholder and executive disclosures from stock exchange databases, including HKEX, SSE, SZSE, and SEC EDGAR.
  • Corporate History: Primary data from annual company reports, founding charters, and verified press announcements.

All information is cross-referenced with public sources for accuracy; some narrative sections are AI-assisted summaries.

If you find any inaccuracies, please report them to admin@redcarpetlife.in

Sponsored Content